(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Land Rover Just Unveiled Its Dakar Rally Defender - 2Old photos misrepresented as aftermath of political party supporters' brawl in Bangladesh
- 3High-Suggested Broilers For Your Homes
- 4Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- 5Surveys of Music Collections by Film Stars
- Must-See Public Parks from Around the Globe
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- Virtual reality opens doors for older people to build closer connections in real life
- Investigating Cooking and Culinary Expressions: An Excursion Through Flavors
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- Which European palace do you fantasy about visiting? Vote!
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
